image: Schematic illustration of recent advances in diagnostic and therapeutic systems based on AENs, including applications in tumor therapy, anti oxidant therapy, anti bacterial therapy
Credit: Pir Muhammad, et al.
Published in the KeAi journal Nano Biomedicine and Engineering, a new review by researchers from Hainan Medical University details how atomically engineed nanozymes (AENs)are engineered to mimic natural enzymes while outperforming them in biomedical applications. These nanostructures can precisely regulate reactive oxygen species (ROS), activate immune pathways, and remodel the tumor microenvironment—killing tumors by immunotherapy.
“From radioimmunotherapy and cuproptosis to ferroptosis and pyroptosis, AENs are being harnessed to induce immunogenic cell death, activate STING pathways, and boost checkpoint blockade therapies,” shares senior author Pir Muhammad. “They also show promise in antibacterial applications, wound healing, and mitigating drug-induced organ toxicity.”
In particular, AENs' atomic tunability allows the design of targeted, efficient, and personalized therapeutic platforms for more effective treatments of different disease, including rheumatoid arthritis, acute pancreatitis, sepsis, Parkinson's disease , ischemic strokes, pneumonia, and Alzheimer's disease.
Nonetheless, the authors note that while AENs show promise, challenges remain in scaling synthesis, long-term biocompatibility, and precise control of catalytic activity in dynamic biological environments. Future efforts are likely to focus on intelligent nanozyme design, real-time immune monitoring, and clinical translation.
###
Contact the author: Yanli Wang, Pir Muhammad, Engineering Research Center of Tropical Medicine Innovation and Transformation of Ministry of Education, International Joint Research Center of Human-machine Intelligent Collaborative for Tumor Precision Diagnosis and Treatment of Hainan Province, School of Pharmacy, Hainan Academy of Medical Sciences, Hainan Medical University, Haikou, Hainan 571199, China pir@muhn.edu.cn
The publisher KeAi was established by Elsevier and China Science Publishing & Media Ltd to unfold quality research globally. In 2013, our focus shifted to open access publishing. We now proudly publish more than 200 world-class, open access, English language journals, spanning all scientific disciplines. Many of these are titles we publish in partnership with prestigious societies and academic institutions, such as the National Natural Science Foundation of China (NSFC).
Journal
Nano Biomedicine and Engineering
Article Title
Atomically engineered nanozymes (AEN): Revolutionizing catalytic immunemodulation for biomedical advances
COI Statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.